Beta Bionics (BBNX) Net Income towards Common Stockholders (2024 - 2026)

Beta Bionics has reported Net Income towards Common Stockholders for 3 years, with the latest figure at -$64.4 million in Q2 2026.

• Quarterly Net Income towards Common Stockholders fell 6.02% year-over-year to -$64.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$205.0 million (down 39.89% YoY) and the FY2025 annual result came in at -$202.7 million, down 97.99% from the prior year.
• Net Income towards Common Stockholders fell to -$64.4 million in Q2 2026 per BBNX's latest filing, from -$43.6 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at -$8.8 million in Q1 2024 and troughed at -$82.8 million in Q3 2025.
• A 3-year average of -$37.2 million and a median of -$29.0 million in 2025 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2025 and 2026: Net Income towards Common Stockholders plunged 669.82% in 2025, then surged 30.09% in 2026.
• Over 3 years, Net Income towards Common Stockholders stood at -$12.7 million in 2024, then decreased by 12.45% to -$14.3 million in 2025, then plunged by 351.16% to -$64.4 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$64.4 million, -$43.6 million, and -$14.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.